NCT05986162View on ClinicalTrials.gov

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

PHASE1UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

May 3, 2025

Study Completion Date

June 25, 2025

Conditions
Dermatomyositis, Adult Type
Interventions
DRUG

Itolizumab

Patients to be treated with Itolizumab.

Sponsors
All Listed Sponsors
lead

Biotech Pharmaceutical Co., Ltd.

OTHER